Welcome to our dedicated page for Aspira Women`s Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women`s Health stock.
Aspira Women’s Health Inc. (formerly trading on Nasdaq under AWH) generates frequent news as a bio-analytical based women’s health company focused on noninvasive, AI-powered diagnostic tests for gynecologic diseases. Its updates often center on the commercial performance of OvaSuiteSM, which includes the OvaWatch® and Ova1Plus® blood tests for assessing ovarian cancer risk in women with adnexal masses.
News coverage commonly includes quarterly and annual financial results, where Aspira reports product revenue, OvaSuite test volumes, gross profit, operating expenses, and net loss. These releases may also describe changes in sales productivity, cost controls, and balance sheet items such as cash, liabilities, and stockholders’ deficit.
Another key category of Aspira news involves its research and development pipeline, particularly the ENDOinform™ program. The company has issued multiple announcements about its milestone-based award from the ARPA-H Sprint for Women’s Health initiative, detailing milestone achievements, associated cash payments, and progress toward a non-invasive, AI-enabled blood test for endometriosis using protein and microRNA biomarkers plus patient data.
Corporate governance and capital markets developments are also frequent topics. Aspira has reported Board and executive appointments, equity and convertible note financings, and changes in its listing status, including a delisting notification from Nasdaq and subsequent trading on OTC markets under related symbols. Together, these news items provide investors and observers with insight into Aspira’s diagnostic portfolio, pipeline evolution, financial condition, and corporate actions.
For anyone tracking AWH-related news, this page aggregates press releases and other coverage related to ovarian cancer risk assessment tests, endometriosis diagnostics development, ARPA-H milestones, financial updates, and boardroom or listing changes.
Aspira Women's Health (QTCQB:AWHL), an AI-enhanced women's health diagnostics company, has appointed Jane Pine Wood to its Board of Directors, effective July 11, 2025.
Wood brings extensive healthcare legal expertise, currently serving as Counsel at McDonald Hopkins, LLC since 2024. She previously held the position of Chief Legal Counsel at BioReference Health, LLC, a clinical diagnostic laboratory focused on oncology, urology, and women's health. Her nearly three-decade career at McDonald Hopkins included building one of the country's largest laboratory and pathology client portfolios.
Aspira Women's Health Inc. (OTCQB:AWHL), an AI-enhanced bio-analytics women's health company, has completed its transition to the OTCQB markets exchange, with trading beginning on May 7, 2025. CEO Mike Buhle emphasized this move as a positive step for shareholders, highlighting the company's strategic focus on cost reduction, controlled capital raises to minimize dilution, and leveraging non-dilutive capital sources for short-term business objectives.
Aspira Women's Health (OTC PINK:AWHL) has successfully submitted its third milestone under the $10 million ARPA-H award program, making it eligible for an additional $1.5 million payment expected in Q2 2025. The milestone focused on analytical development steps, including a biomarker technical report and voice of customer study framework for their ENDOinform™ program.
The company has already secured $3.5 million through three milestone submissions and anticipates receiving $2.0 million in fourth and fifth milestone payments by end-2025, with the remaining $3.0 million expected in 2026. The funding supports Aspira's development of an AI-enabled multi-marker blood test for endometriosis detection, leveraging technology from their successful ovarian cancer risk assessment tests.
Aspira Women's Health (NASDAQ:AWH), a bio-analytical based women's health company specializing in gynecologic disease diagnostic tools, has announced a trading symbol change. Starting April 17, 2025, the company's Common Stock will transition from trading under 'AWH' to trading under the new symbol 'AWHL' on the OTC Markets Group platforms.
Aspira Women's Health (NASDAQ:AWH) has received a delisting notification from Nasdaq on April 15, 2025. The company's shares will be suspended from trading on Nasdaq effective April 17, 2025, due to non-compliance with Nasdaq Listing Rule 5550(b)(1), which requires maintaining a minimum stockholders' equity of $2.5 million for continued listing on the Nasdaq Capital Market.
Following the suspension, AWH's common stock is expected to transition to trading on OTC markets under the same symbol 'AWH'. The company, which focuses on developing gynecologic disease diagnostic tools, will no longer maintain its Nasdaq listing status.
Aspira Women's Health (NASDAQ:AWH) has announced significant board changes with the appointment of three new directors: Dr. Jeffrey Cohen, Cindy Hundorfean, and Jack Fraser. Dr. Cohen brings over 40 years of urological expertise and robot-assisted surgery experience, while Hundorfean contributes senior healthcare leadership experience as a partner at The CEO Advisory Network. Fraser adds financial expertise from his 25-year tenure at Seamark Capital.
The company also executed a $2.0 million equity purchase agreement with Triton Funds LP. The proceeds will support ongoing commercial activities, working capital, and general corporate purposes. A key focus remains on driving sales growth and completing their current endometriosis clinical study for the ENDOInform™ blood test.
Dr. Celeste Fralick will be departing the board after serving since February 2022. The board changes align with the upcoming annual shareholders meeting.
Aspira Women's Health (NASDAQ:AWH) has successfully achieved the second milestone of its $10 million ARPA-H Sprint for Women's Health award, receiving a $1.5 million payment. The milestone focused on scaling up R&D capabilities for developing ENDOinform™, a non-invasive blood test for endometriosis detection.
The project involves developing an AI-enabled algorithm combining protein and microRNA biomarkers with patient data. The second milestone included plans for building a new molecular laboratory, securing patents and licenses, and conducting market research for test positioning.
The company expects to complete the third milestone in Q2 2025, which will trigger another $1.5 million payment upon delivery of a biomarker algorithm technical report and voice of customer study framework. The program will continue through early 2026, providing non-dilutive funding for Aspira's growth.
Aspira Women's Health (AWH) reported its Q4 and full-year 2024 financial results, achieving record OvaSuite revenue of $9.2 million and 24,305 units sold. Q4 2024 highlights include:
- Product revenue up 9.5% to $2.3M
- OvaSuite tests increased 6.1% to 6,004 units
- Average unit price rose 4.3% to $391
- Gross profit margin improved to 63.4%
- Operating expenses decreased 8% to $4.9M
Full-year 2024 performance showed flat product revenue at $9.2M, with test volume up 1.3% and average unit price down 1% to $378. The company raised $5.75M through convertible notes ($1.36M) and ATM facility ($4.39M). Cash balance stands at $3.7M, with an additional $1.5M ARPA-H milestone payment pending.